Table 1.

Characteristics of prostate cancer cases at the time of prostatectomy, HPFS

Telomere length variability among prostate cancer cells and telomere length in prostate CAS cellsa
All menbLess variable/longerMore variable/longerLess variable/shorterMore variable/shorterPc
Number of men596989128098
Mean ± SD age at diagnosis, y65.3 ± 6.165.7 ± 6.465.6 ± 6.265.0 ± 6.065.9 ± 6.20.51
White (%)91.187.889.093.987.80.12
Mean ± SD year of diagnosis, y1,994.2 ± 3.21,994.7 ± 3.31,994.6 ± 3.41,993.8 ± 3.11,994.5 ± 3.10.04
Prostatectomy Gleason sum, %
 ≤621.321.411.023.913.30.006
 3 + 435.842.935.135.730.6
 4 + 324.823.529.725.426.5
 ≥818.112.224.215.029.6
Pathologic stage ≥T3b, %12.65.118.712.117.30.02
Serum PSA concentration at diagnosis in ng/mL, %
 <1059.273.554.957.554.10.17
 10–2017.614.317.617.520.4
 >2010.14.114.310.711.2
 Unknown13.18.113.214.314.3
  • aAmong men for whom telomere length could be determined for both prostate cancer cells and prostate CAS cells (N = 567).

  • bAmong all men.

  • cFrom a χ2 test for proportions and a one-way ANOVA for mean.